Literature DB >> 7468764

Complement-induced granulocyte aggregation in vivo.

D E Hammerschmidt, P D Harris, J H Wayland, P R Craddock, H S Jacob.   

Abstract

Previous studies from our laboratories have demonstrated that granulocytes (PMNs), when exposed to activated complement (C) (specifically C5a), will aggregate and be provoked to damage cultured endothelial cells in vitro; it was postulated that these phenomena might also occur in vivo, constituting a previously unsuspected mechanism of immune tissue damage. The studies here presented confirm by intravital microscopy that PMN aggregation and leukoembolization in fact occur in live animals when C is activated or C5a is infused, and that these are accompanied by extravasation of plasma proteins in a pattern suggesting endothelial damage. It is concluded that altered microvascular behavior of PMNs is a possible pathogenetic mechanism in disease states associated with C activation.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7468764      PMCID: PMC1903687     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  15 in total

Review 1.  Granulocyte-complement interaction. A beneficial antimicrobial mechanism that can cause disease.

Authors:  H S Jacob
Journal:  Arch Intern Med       Date:  1978-03

2.  Quantitative fluorescent tracer studies in vivo.

Authors:  H Wayland; J R Fox; M D Elmore
Journal:  Bibl Anat       Date:  1975

3.  Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia.

Authors:  P R Craddock; D Hammerschmidt; J G White; A P Dalmosso; H S Jacob
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

4.  Laser stimulation of fluorochromes in intravital microscopy using a mirror objective.

Authors:  H Wayland
Journal:  Bibl Anat       Date:  1973

5.  Profound neutropenia during the early phase of hemodialysis.

Authors:  L S Kaplow; J A Goffinet
Journal:  JAMA       Date:  1968-03-25       Impact factor: 56.272

6.  Membrane properties of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters.

Authors:  B Rotman; B W Papermaster
Journal:  Proc Natl Acad Sci U S A       Date:  1966-01       Impact factor: 11.205

7.  Potentiation of complement (C5a)-induced granulocyte aggregation by cytochalasin B.

Authors:  P R Craddock; J G White; H S Jacob
Journal:  J Lab Clin Med       Date:  1978-03

8.  In vitro bactericidal capacity of human polymorphonuclear leukocytes: diminished activity in chronic granulomatous disease of childhood.

Authors:  P G Quie; J G White; B Holmes; R A Good
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

9.  Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis.

Authors:  P R Craddock; J Fehr; K L Brigham; R S Kronenberg; H S Jacob
Journal:  N Engl J Med       Date:  1977-04-07       Impact factor: 91.245

10.  Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.

Authors:  P R Craddock; J Fehr; A P Dalmasso; K L Brighan; H S Jacob
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  26 in total

1.  Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.

Authors:  David R W Jayne; Annette N Bruchfeld; Lorraine Harper; Matthias Schaier; Michael C Venning; Patrick Hamilton; Volker Burst; Franziska Grundmann; Michel Jadoul; István Szombati; Vladimír Tesař; Mårten Segelmark; Antonia Potarca; Thomas J Schall; Pirow Bekker
Journal:  J Am Soc Nephrol       Date:  2017-04-11       Impact factor: 10.121

2.  Paraquat-induced neutrophil alveolitis: reduction of the inflammatory response by pretreatment with endotoxin and hyperoxia.

Authors:  W J Martin; D M Howard
Journal:  Lung       Date:  1986       Impact factor: 2.584

Review 3.  Endothelium-neutrophil interactions in ANCA-associated diseases.

Authors:  Lise Halbwachs; Philippe Lesavre
Journal:  J Am Soc Nephrol       Date:  2012-09       Impact factor: 10.121

4.  Evidence that prolonged histamine suffusions produce transient increases in vascular permeability subsequent to the formation of venular macromolecular leakage sites. Proof of the Majno-Palade hypothesis.

Authors:  K L Horan; S W Adamski; W Ayele; J J Langone; G J Grega
Journal:  Am J Pathol       Date:  1986-06       Impact factor: 4.307

5.  Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro.

Authors:  K M Skubitz; P R Craddock; D E Hammerschmidt; J T August
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

6.  Ibuprofen inhibits granulocyte responses to inflammatory mediators. A proposed mechanism for reduction of experimental myocardial infarct size.

Authors:  P J Flynn; W K Becker; G M Vercellotti; D J Weisdorf; P R Craddock; D E Hammerschmidt; R C Lillehei; H S Jacob
Journal:  Inflammation       Date:  1984-03       Impact factor: 4.092

7.  Correlation between CD11b/CD18 and increase of aggregability of granulocytes in coronary artery disease.

Authors:  A Mazzone; D Pasotti; S De Servi; G Fossati; I Hazzucchelli; P Cavigliano; G Ricevuti
Journal:  Inflammation       Date:  1992-08       Impact factor: 4.092

8.  Aggregation of human polymorphonuclear leucocytes during phagocytosis of bacteria.

Authors:  P A Henricks; M E van der Tol; J Verhoef
Journal:  Immunology       Date:  1984-08       Impact factor: 7.397

9.  Characterization of polymorphonuclear leukocyte aggregation in vitro induced by heat-inactivated group B streptococcus.

Authors:  P C Panus; G L Longenecker; S A Chartrand; R C Boerth; K J Peevy
Journal:  Inflammation       Date:  1987-03       Impact factor: 4.092

10.  Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue.

Authors:  R Huey; C M Bloor; M S Kawahara; T E Hugli
Journal:  Am J Pathol       Date:  1983-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.